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Abbreviations
•   PMTCT – Prevention of mother to child transmission
•   TB – Tuberculosis
•   HBV – Hepatitis B virus
•   HCC – Hepatocellular carcinoma
•   WHO – World Health Organisation
•    HIV/AIDS – Human Immunodeficiency Virus/Acquired 
Immunodeficiency Syndrome
•   HCWs – Healthcare workers
•   THs – Traditional healers
•   CHB – Chronic Hepatitis B
Introduction
Hepatitis B virus (HBV) infection has been reported worldwide, 
with an estimated burden of 250 million cases, and has been 
associated with high mortality rates resulting from complica-
tions including cirrhosis and hepatocellular carcinoma (HCC)1. 
There are effective prevention and treatment strategies available, 
including vaccination and suppressive antiviral therapy, both of 
which also contribute to prevention of vertical transmission2. 
The Global Hepatitis Health Sector Strategy is aiming for the 
elimination of viral hepatitis as a public health threat by 20303. 
However, there are important challenges still to be addressed 
including gaps in vaccine coverage1,4, limited access to diagnos-
tic tests and treatment1 and lack of a curative therapy2,4. Stigma, 
poverty, and lack of knowledge add further to the challenge, 
especially in resource-limited settings2. There is a growing 
body of personal testimonies providing evidence of stigma asso-
ciated with HBV5,6. However, there is a very limited literature 
to describe this, and more work is required to understand 
the nature and impact of stigma for individuals with HBV 
infection.
Individuals who are stigmatised as a result of illness or infec-
tion not only have to bear potential challenges to health, but may 
also be denied the opportunities that define quality of life such 
as education, employment, access to appropriate health care and 
interaction with a diverse cross-section of society7. Although 
many diseases are stigmatised, awareness of – and investi-
gation into – stigma is better represented in some areas than 
others. In HIV, stigma has been shown to limit engagement 
with services including screening and prevention of mother 
to child transmission (PMTCT), and uptake of antiretroviral 
therapy8–11; in tuberculosis (TB) it has been shown to cause 
diagnostic delays and treatment non-compliance12,13, and in 
mental illness, stigma has been associated with delays in help-
seeking, discontinuation of treatment, suboptimal therapeutic 
relationships, patient safety concerns, and poorer quality mental 
and physical care14–16.
Stereotypes and prejudice may stem from physical differences 
attributable to the condition, misconceptions associated with fear 
of contagion, and judgements about routes of transmission, 
all of which may be underpinned by lack of knowledge17–19. 
Beyond the physical manifestations and potential complications 
of an illness, stigma usually arises from lack of awareness, 
lack of education and lack of perception20. People living with 
HIV/AIDS, especially those displaying wasting syndrome and 
certain identifiable opportunistic infections are more prone 
to stigma compared to those who are asymptomatic8. HIV and 
TB may be stigmatised as a result of anxieties about spread 
of infection, and may also be regarded as a punishment for 
‘irresponsible’ or ‘immoral’ behaviour,13,21–23. People with mental 
illnesses may be considered ‘dangerous’ or provoke fear, 
may lose their autonomy, or be treated as ‘childlike’7. Under-
standing why society reacts in a particular way is one way to 
address stigma18, and could therefore help to guide approaches 
to tackling stigma in HBV.
HBV is highly endemic in Africa, a continent that faces huge 
challenges in prevention, diagnosis and treatment1. The situ-
ation is further complicated by the substantial public health 
challenge of co-endemic HIV and HBV24. An understanding of 
the breadth and scope of stigma in HBV, especially in Africa, is 
an essential part of any strategy that seeks to tackle and even-
tually eliminate HBV infection as a public health problem. 
As the improvement of universal availability and accessibil-
ity of diagnostic, treatment and vaccination options are under-
way, it is important to ensure that products and services are not 
only available, but also accessible; people with HBV infec-
tion must be able to access education, clinical care, and sup-
port from their partners and families, healthcare workers, 
and members of their communities. Also, the WHO recom-
mends HBV treatment in an environment that minimizes stigma 
and discrimination25.
We therefore set out to assimilate evidence for the nature and 
impact of stigma on the lives of people with HBV infection 
and on the community, to describe coping strategies employed 




In November-December 2017, we undertook a literature search 
in PubMed; our search strategy is detailed in Supplementary 
file 1. We carried out two searches: the first search focused 
on stigma in HBV in Africa; and a second search which was 
not limited to Africa. These searches yielded 50 and 879 arti-
cles, respectively. 49 articles were duplicates. On reviewing the 
titles and abstracts, 827 were excluded from search results as 
they were not on stigma or HBV. Full texts of 53 articles were 
reviewed and 19 were excluded (3 were reviews, 3 were reports, 
1 was not available, and 12 did not report on stigma). A total of 
34 articles were therefore downloaded in full (Supplementary 
file 3). From each publication, we extracted: citation, study 
design, sample size, study population, country, factors associ-
ated with stigma, impact of stigma on the lives of people with 
HBV, and proposed interventions to tackle stigma in the society. 
Data were curated using MS Excel software (Microsoft, 
Redmond, WA). Ethics approval was not required for this study.
Results
The full metadata generated from our literature search are 
available in Supplementary file 2.
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Factors associated with creating or perpetuating stigma for 
individuals with HBV infection
Some of the common themes identified from literature that 
are associated with stigma and HBV are summarised in 
Table 1.
Lack of knowledge is a central theme in perpetuation of stigma. 
This applies to education among individuals with the infection, 
but also their families, society and health care workers (HCW). 
Failure of HCWs to provide adequate and accurate informa-
tion may be a barrier to treatment, reduce the likelihood of 
disclosure to family, and contribute to fear, anxiety and depres-
sion which in turn negatively impact on coping strategies26. 
Lack of knowledge may also be a reason why some HCWs 
are not themselves vaccinated against HBV and therefore 
are at an increased risk of acquiring HBV. A study carried 
out in Cameroon reported a HBV vaccination rate of only 
12% among HCW27, and a study in Nigeria reported a 25% 
prevalence of HBV infection among surgeons28. Lack of aware-
ness among policy makers negatively impacts on appropriate 
prioritisation, and this can be an important contributor to poor 
advocacy, inadequate allocation of resources29 and poor levels 
of education.
Given that HBV is not well understood in some communi-
ties, it may be considered a punishment or linked to ‘evil 
spirits’26,30,31. Some individuals may therefore opt to seek assistance 
from traditional healers (THs) or faith leaders, seeking ‘purifica-
tion’. Although THs and religious healers can have an impor-
tant role in providing psychosocial support, there is also the 
potential for harm and/or delaying presentation to clinical 
care32,33. A recent report showed that in Africa, HCC presents at 
a late stage, where effective treatment would be challeng-
ing for any healthcare system34. Specialised training on HBV 
for THs and ministers of faith, and healthcare programs that 
work collaboratively with these groups, could be a valuable 
approach in some settings35.
Although stigma has also been associated with old age and 
following of traditional values36, this may primarily reflect 
lack of knowledge or exposure, while younger people tend to 
have more access to information, and are less defined by tradi-
tional values36,37. However, this relationship is not consistent, as 
one study found an association between old age and decreased 
prejudice in HBV infection38. It is important to pay special 
consideration to specific groups of people who might be most 
vulnerable to the effects of stigma when designing interventions.
Stigma affects various aspects of everyday lives of people 
with HBV infection (Table 2). Similar to mental disorders 
and HIV/AIDS, stigma in HBV can negatively impact on 
health behaviour such as help-seeking, screening, disclosure, 
prevention of transmission, access and adherence to treatment, 
and poorer quality mental and physical care8,14,20.
Table 1. Factors underpinning stigma in HBV infection, identified from a literature review.
Lack of knowledge or awareness
Lack of knowledge among the public was represented by:
•   Misconceptions that HBV can be transmitted through sharing of utensils, via food or eating together39–46;
•   Beliefs that HBV is a genetic trait47;
•   Lack of awareness that HBV could be transmitted sexually41;
•    Representation of HBV as a consequence of bad behaviour, or perception of individuals with HBV as  
‘bad’ people31.
Lack of knowledge among healthcare workers (HCWs) was represented by:
•   Lacking or inaccurate information provided by HCWs regarding HBV diagnosis or treatment40,48;
•   Provision of inappropriate reassurance, or overemphasisis of potential complications48;
•   Poor understanding among HCWs regarding appropriate laboratory testing to diagnose HBV infection44;
Lack of knowledge among individuals with HBV was represented by:
•   Lack of necessary precautions for prevention of transmission30;
•   Difficulty processing information about the infection, leading to anxiety or depression48;
•    Pursuit of traditional or religious interventions reflecting the belief that infection may be caused by evil 
spirits26,30.
Other factors associated with stigma
Stigma in HBV has been associated with:
•    Extremes of age (In some cases this is evident in older age36,37,41,49 and in other reports, in younger age groups38);
•   People strongly defined by traditional values37,41;
•   Lower education levels36,37;
•   People who have not themselves been screened or vaccinated against HBV49.
Among HCWs, hesitance to provide care to individuals with HBV infection was noted among:
•   Those who had not come across or offered healthcare to an individual with HBV infection50,51;
•    Those who perceived an infection risk to themselves52 or had low individual confidence in protecting themselves53.
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Table 2. Evidence for the impact of HBV infection, identified from a literature review.
Reduced access to appropriate health care
•   Stigma is associated with reduced uptake of opportunities for diagnostic screening and clinical care30,39,44,47,54,55.
Impact on family and relationships
People living with HBV infection:
•    May be anxious about spreading the infection to family members, and therefore distance themselves from close 
relationships36,39,40,43,56;
•   Report feeling of bringing shame upon the family54,57,58;
•   Can experience difficulties in establishing and/or maintaining intimate relationships40,54.
Impact on work and career
•   HBV may lead to inappropriate exclusion from certain career choices (e.g. healthcare, childcare, food handling)54,59,60;
•   Individuals with HBV infection are discriminated against at work, lose employment, or are unable to find work47,56.
Impact on mental health
People living with HBV infection:
•    May fear the physical consequences of disease progression and/or treatment side effects39,56; this fear can perpetuate 
discrimination49;
•    May have negative self-image and experience feelings of guilt and shame41; these are associated with shame about 
disclosing diagnosis36;
•   May experience anxiety about economic cost of treatment56;
•   Fear being stigmatised61;
•   May suffer significant psychosocial morbidity, which can be more substantial than physical symptoms59;
•   May face deportation if not resident in their country of origin62;
•   May seek privacy and suffer fear of disclosure; this can be distinct in African communities37.
•   Report feeling humiliated, embarrassed, or inferior, together with a sense of guilt and shame57.
Impact on social behavior
People living with HBV infection may suffer the following social discrimination:
•   Are not allowed to share utensils / food / towels / soap, for fear of transmitting the infection36,40,54,63;
•   Suffer feelings of rejection or isolation, including perceptions that other people are avoiding them40,57,59,63;
•    Suffer feelings of ‘passivity’ because of lack of treatment, or cost of treatment, which results in missing opportunities to 
start treatment and defaulting clinical follow-up48;
•   Develop a habit of secrecy, in order to avoid disclosure62,64.
Relationship with education / knowledge
•   Stigma may contribute to lack of awareness65;
•   Lack of education about HBV is associated with discrimination42;
•    There is less stigma if people are more educated or if they have a family member with HBV43,58; conversely, familiarity with 
the disease and higher levels of knowledge have been associated with lower stigma43,54;
•    There is a lack of concordance as to whether education/knowledge makes stigma towards HBV better or worse – e.g. in 
some studies, those with more education were more worried36.
Coping strategies and interventions for HBV stigma
Coping strategies that have been described for HBV are 
listed (Table 3). Depending on the coping strategies used, not 
everyone experiencing stigma will necessarily suffer emotional 
distress or have diminished well-being as a consequence66. In 
HIV, avoidant coping strategies such as denial have been associ-
ated with higher levels of depression whereas acceptance of the 
diagnosis, associated with personal control and self-efficacy, 
is associated with reduced levels of depression67. Among 
patients with schizophrenia, the ability to use positive coping 
strategies was associated with reduced self-stigma68. Further 
studies are needed to explore coping strategies used to deal 
with HBV stigma, to exploring the choice of coping strategy, 
and to determine outcomes.
As well as individual coping strategies, a variety of other 
interventions have been proposed to tackle stigma (Table 3). 
In many cases, attitudes may improve after realising that 
infection can be prevented and managed therapeutically31. This 
is in line with a report from the WHO about mental illness, 
highlighting that stigma can be combated through educational 
messages representing conditions as illnesses that respond to 
specific treatment69.
Counselling can provide several benefits, alleviating anxiety 
associated with a new diagnosis, as well as providing an oppor-
tunity to share factual information regarding treatment, preven-
tion, self-care and overall well-being26,48. Counselling should 
cover a broad range of information such as the natural history 
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of the disease, diagnosis, treatment, prevention and living 
with the infection26. This should be delivered sensitively, at a 
time and in a manner that supports the individual in accepting 
and processing the information.
There are several strategies that have been used to raise aware-
ness of HIV/AIDS which could be applied to HBV. Dissemi-
nation of factual information through use of radio, television, 
posters, pamphlets and drama has been widely used to diminish 
stigma towards HIV in resource limited settings8. Multiple edu-
cational sessions can also be an effective way of increasing 
awareness and therefore reducing stigma, as participants have 
the opportunity to reflect on the concepts learnt in the pre-
vious sessions74. Another successful method for training 
HCWs is perspective-taking and empathy: participation is 
associated with ‘increased willingness to treat people with 
certain illnesses, decreased stigma and increased awareness 
of confidentiality among healthcare workers’74. These 
approaches could be used to tackle HBV stigma among HCWs 
and community members.
On-line support groups provide a platform for people liv-
ing with HBV to share their experiences5, and charities can be 
influential in raising awareness, and promoting important health 
messages5,75. The internet is widely used as a tool for sharing 
experiences, and as such can raise awareness of stigma6, as 
well as uniting individuals and communities as a support 
network. It is important for HCWs to introduce newly diagnosed 
individuals to these avenues to help people living with HBV. 
Importantly, more charities and support groups that are 
well suited for people with HBV infection in Africa are needed.
Discussion
Despite the limited evidence from Africa, the data we have gath-
ered reflect consistent themes in stigma and discrimination 
affecting individuals with chronic viral hepatitis infection. 
These may have a wide-reaching influence on physical health 
(for example inhibiting interaction with clinical services and 
reducing treatment adherence), psychological well-being 
(through increasing isolation, anxiety and depression), and 
interactions with family and the wider society (by limiting 
relationships, social interactions and employment opportunities). 
Recognising, understanding and tackling the issue of this stigma 
in African populations could be a valuable tool to improve 
population health and to underpin advances towards elimination 
strategies proposed for the year 2030.
Limitations and caveats
There are very few data to inform this discussion: we iden-
tified only two studies on stigma from Africa26,76 and three 
other studies included African participants in North America37, 
Australia65 and in UK77. Although we did a robust search of 
the peer-reviewed scientific literature, there may be other 
sources that are not captured by this scientific style of approach. 
Most studies had very small sample sizes and some were oppor-
tunistic in recruiting participants, thus limiting generalisability 
of the findings. We have therefore also drawn on the 
literature for HIV, TB and mental illness.
Future aspiration and challenges
Studies looking at stigma may benefit from a mixed method 
study design, providing stronger evidence and increasing 
generalisability of the findings. It is important to carry out 
research on stigma with the aim of demonstrating its burden 
and its effects, while also considering how to establish and 
evaluate interventions that tackle stigma within communities. We 
identified only one study that evaluated the effectiveness of 
stigma reduction programmes among Asians in USA31. More 
studies like this are needed in Africa as they will also help to 
deploy resources in the most appropriate and effective ways. 
Table 3. Coping strategies and other interventions that have been used to tackle stigma in HBV, identified from a literature 
review.
Coping strategies for individuals with HBV infection
•   Seeking words of encouragement and prayers from spiritual leaders or family members26,37;
•   Lifestyle modification, such as reduced intake of alcohol and fatty foods26;
•   Reaching out for support from family members and friends70;
•   Use of support groups5;
•    Note that certain coping strategies may also result in negative influences, such as avoiding disclosure37, disengagement 
from seeking active treatment48, and emotional responses including grief, denial, anger and aggression26,57.
Coping strategies associated with negative influence
•    Establishing culturally appropriate public education or awareness programmes that promote surveillance and 
treatment30,36,37,39,41,42,48,49,58,71,72. One study presented a real-life narrative where influential people from that community talked 
about their experiences with HBV, emphasising the availability of treatment and prevention strategies31.
•    Providing specialised training about HBV infection, which may be designed to target people living with HBV, HCWs, THs, 
the wider public26,30,35,39,46,48,50,72,73;
•    Training of policy makers and healthcare professionals on the urgency of tackling HBV, and on prevention, diagnosis and 
treatment30,39,40,48,72;
•   Training of healthcare workers to provide pre- and post-test counselling26,48,56;
•    Developing national campaigns to promote HBV screening and vaccination. Screening and vaccination can reduce social 
stigma surrounding HBV36.
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In addition to raising awareness among individuals with HBV 
infection, the general public and HCWs, enhanced communica-
tion with policy makers is also crucial. Despite the high burden 
of HBV in low and middle-income countries, there is 
limited infrastructure to support diagnosis and treatment, and 
disproportionately little international research funding for 
HBV compared to other infectious diseases2.
Conclusion
Stigma is a potentially major barrier to the successful imple-
mentation of preventive, diagnostic and treatment strategies 
for HBV infection, and yet there is very limited recognition 
of the magnitude of this challenge, especially in Africa. Lack 
of knowledge among policymakers, HCWs, the general 
public and patients is a potent driver of stigma. Stigma in turn, 
negatively impacts health behaviour such as help-seeking, 
screening, disclosure, prevention of transmission and adher-
ence to treatment. Establishing education programmes and 
awareness campaigns is crucial. There is also a pressing need 
for more research in this area, to identify and evaluate inter-
ventions that can be used effectively to tackle stigma in HBV, 
and for collaborative efforts between policy makers, HCWs, 
traditional healers, religious leaders, charity organisations and 
support groups, to improve awareness and tackle stigma in HBV 
in Africa.
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